Immunohistochemical expression of TROP‑2 (TACSTD2) on the urothelial carcinoma of the urinary bladder and other types of cancer

In metastatic or locally advanced urothelial carcinoma (UC), therapeutic options have been limited to chemotherapy and immune checkpoint inhibitors. Novel targets and drugs such as antibody drug conjugates have been developed, and enfortumab vedotin targeting nectin-4 and sacituzumab govitecan (SG)...

Descripción completa

Detalles Bibliográficos
Autores principales: Abbas, Mahmoud, Heitplatz, Barbara, Bernemann, Christof, Boegemann, Martin, Trautmann, Marcel, Schrader, Andres Jan, Wardelmann, Eva, Schlack, Katrin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644361/
https://www.ncbi.nlm.nih.gov/pubmed/38020299
http://dx.doi.org/10.3892/ol.2023.14114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10644361/
https://www.ncbi.nlm.nih.gov/pubmed/38020299
http://dx.doi.org/10.3892/ol.2023.14114

Ejemplares similares